secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001193125-24-064372
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience appoints former Biogen CMO Maha Radhakrishnan to board
------------------------------------------------------------------------

- Dr. Radhakrishnan, age 54, appointed as Class I director effective March 8, 2024; term expires at 2025 Annual Meeting.
- Former Group SVP and Chief Medical Officer at Biogen (Jan 2020 – Mar 2024); earlier roles at Sanofi and Bioverativ.
- Board determined she is independent under NYSE and SEC rules; will serve on Nominating and Corporate Governance Committee.
- Receives initial option for 30,574 shares vesting over 3 years, annual option for 15,287 shares, and cash retainers ($40k board + $5k NCGC).
- Company entered standard indemnification agreement with Dr. Radhakrishnan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000119312524064372/0001193125-24-064372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000119312524064372/d764642d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-064372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer